ロード中...
Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension
Intravenous epoprostenol is recommended for World Health Organization functional class (WHO-FC) IV patients with pulmonary arterial hypertension (PAH) in the latest guidelines. However, in portopulmonary hypertension (PoPH) patients, advanced liver dysfunction and/or thrombocytopenia often makes the...
保存先:
| 出版年: | World J Hepatol |
|---|---|
| 主要な著者: | , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Baishideng Publishing Group Inc
2014
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4243157/ https://ncbi.nlm.nih.gov/pubmed/25429321 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4254/wjh.v6.i11.825 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|